Equity Details
Price & Market Data
Price: $0.84
Daily Change: +$0.005 / 0.60%
Daily Range: $0.83 - $0.87
Market Cap: $30,071,144
Daily Volume: 42,282
Performance Metrics
1 Week: -12.30%
1 Month: 17.19%
3 Months: -18.33%
6 Months: -10.43%
1 Year: -24.27%
YTD: 8.32%
About NeuroSense Therapeutics Ltd. (NRSN)
Your comprehensive guide to NeuroSense Therapeutics Ltd. (NRSN). Price: 0.84, daily change: +$0.005 / 0.60%. Market cap: 30,071,144. Full range of performance data for investors.
Company Details
Employees: 16
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.